by The joint pain injections market size is predicted to reach USD 7.59 billion by 2030 and is expected to register a CAGR of 6.9% from 2022 to 2030.
The study provides an analysis of the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
The market revenue/volume with the help of widespread quantitative and qualitative insights, and forecasts of the market. This report presents a breakdown of the market into forthcoming and niche segments. Additionally, this research study gauges market revenue growth and its drift in global, regional, and country from 2017 to 2030.
Download a Free Sample Copy of this Report@ https://www.precedenceresearch.com/sample/1449
The geriatrics and the elderly are the most commonly affected by joint problems. The ripping of synovial fluid in the joints caused by injury or ageing causes joint discomfort. Hyaluronic acid, which is found in the synovial fluid, lubricates the spaces between the joints. Hyaluronic acid helps to reduce joint inflammation and pain caused by tissue deterioration and injury. During an injury, hyaluronic acid breaks down, causing joint discomfort and inflammation in the ligaments and tendons that surround the joint.
Osteoarthritis, which is caused by a loss of synovial fluid in the joint area, is a very frequent condition among the elderly. One of the joint pain injections contains hyaluronic acid and are injected directly into the joints to assist alleviate inflammation and pain by filling and lubricating the afflicted area. Psoriatic arthritis, bursitis, gout, osteoarthritis, and other types of joint discomfort are commonly treated with joint pain injections.
Table of Contents
Scope of the Joint Pain Injections Market
| Report Coverage | Details |
| Market Size In 2021 | USD 4.16 Billion |
| Growth Rate From 2021 to 2030 | CAGR of 6.9% |
| Revenue Projection By 2030 | USD 7.59 Billion |
| Largest Market | North America |
| Fastest Growing Marklet | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Injection Type, Distribution Channel, Region |
Market Dynamics
Drivers
Increasing demand for hyaluronic acid injections
The injections segment for joint pain injections market is led by hyaluronic acid injection. Because human joints are like gears that are constantly subjected to wear and tear, hyaluronic acid has excellent lubrication and shock-absorbing properties similar to synovial fluid, reducing joint stiffness and tenderness. Because of its anti-inflammatory properties and ability to provide short-term relief in joint sprains experienced by athletes and industrial workers, corticosteroid injections are used as an adjuvant medication in joint pain. Thus, the increasing demand for hyaluronic acid injections is driving the growth of join pain injections market during the forecast period.
Restraints
Shortage of arthritis specialists
The arthritis is observed mainly in the old age people. The use of joint pain injections requires specialists. But due to lack of resources and knowledge, there is shortage of arthritis specialists in various regions. The shortage of arthritis specialists in developing and underdeveloped regions is one of the restricting factors for the growth of market. On the other hand, the high costs of arthritis injections also hinder the growth of the market. As a result, the shortage of arthritis specialists is expected to hinder the growth of joint pain injections market during the forecast period.
Opportunities
Growing geriatric population
The geriatric population is rapidly growing. According to the United Nations, more than 727 million people are 65 or older. Joint pain and other diseases are common among the elderly population. People aged 65 and up are not in good physical shape. They are unable to visit healthcare clinics and hospitals on a regular basis for health checks. As a result, joint pain injections can be used on a large scale by the geriatric population to avoid frequent hospital visits. As a result, during the forecast period, the growing geriatric population creates new lucrative opportunities for the growth of the joint pain injections market.
Challenges
Lack of awareness about the products
The people are not aware about the joint pain injections. The joint pain injections such as hyaluronic acid injections, corticosteroid injections, and platelet-rich plasma injections. The use of these injections requires proper knowledge and training. The utilization of joint pain injections on patients is mainly done by doctors and healthcare experts. For this, the proper and training is provided to professionals. The lack of government initiatives for the promotion of joint pain injections is a restraint factor for the market. As a result, the lack of awareness about the products is a huge challenge for the growth of joint pain injections market during the forecast period.
Read Also: Materials Informatics Market Growth at 29.2% CAGR During 2021 To 2027
Report Highlights
Based on the injection type, the hyaluronic acid injections segment dominated the global joint pain injections market in 2020 with highest market share. Hyaluronic acid injections are used to treat osteoarthritis-related knee discomfort. Hyaluronic acid injections are given to individuals who have failed to respond to pain medications and other treatments. Hyaluronic acid acts as a lubricant and stress absorber in the joints, allowing them to function properly.
Regional Snapshot
Asia-Pacific is expected to witness largest CAGR during the forecast period 2021 to 2030. Asia-Pacific dominates the global joint pain injections market due to rising healthcare expenditures and increased investments in the future years.
North America region accounted largest revenue share in 2020. Due to a huge patient pool and rising disease prevalence, an increase in the senior population, increased obesity, and a high adoption of innovative treatments for joint pain reduction in the region, North America region dominated the global joint pain injections market.
Key Points Covered in joint pain injections market Study:
- Growth of joint pain injections in 2022
- Market Estimates and Forecasts (2017-2030)
- Market Share Analysis
- Key Drivers and Restraints Shaping Market Growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Recommendation on Key Winning Strategies
- COVID-19 Impact on Demand for joint pain injections and How to Navigate
- Key Product Innovations and Regulatory Climate
- Consumption Analysis
- Production Analysis
- Market and Management
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Joint Pain Injections Market
5.1. COVID-19 Landscape: Joint Pain Injections Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Joint Pain Injections Market, By Product
8.1. Joint Pain Injections Market, by Product Type, 2021-2030
8.1.1. Pre-filled injections
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Vials
8.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Joint Pain Injections Market, By Injection
9.1. Joint Pain Injections Market, by Injection, 2021-2030
9.1.1. Corticosteroid Injections
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Hyaluronic Acid Injections
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Platelet-rich Plasma Injections
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Placental tissue matrix (PTM) Injections
9.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Joint Pain Injections Market, By Joint Type
10.1. Joint Pain Injections Market, by Joint Type, 2021-2030
10.1.1. Knee and Ankle
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Hip
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Shoulder and Elbow
10.1.3.1. Market Revenue and Forecast (2019-2030)
10.1.4. Spinal Joints
10.1.4.1. Market Revenue and Forecast (2019-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Joint Pain Injections Market, By Distribution Type
11.1. Joint Pain Injections Market, by Distribution Type, 2021-2030
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2019-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2019-2030)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 12. Global Joint Pain Injections Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.2. Market Revenue and Forecast, by Injection (2019-2030)
12.1.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.1.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.5.2. Market Revenue and Forecast, by Injection (2019-2030)
12.1.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.1.6.2. Market Revenue and Forecast, by Injection (2019-2030)
12.1.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.2. Market Revenue and Forecast, by Injection (2019-2030)
12.2.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.2.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.5.2. Market Revenue and Forecast, by Injection (2019-2030)
12.2.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.6.2. Market Revenue and Forecast, by Injection (2019-2030)
12.2.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.7.2. Market Revenue and Forecast, by Injection (2019-2030)
12.2.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.2.8.2. Market Revenue and Forecast, by Injection (2019-2030)
12.2.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.2. Market Revenue and Forecast, by Injection (2019-2030)
12.3.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.3.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.5.2. Market Revenue and Forecast, by Injection (2019-2030)
12.3.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.6.2. Market Revenue and Forecast, by Injection (2019-2030)
12.3.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.7.2. Market Revenue and Forecast, by Injection (2019-2030)
12.3.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.3.8.2. Market Revenue and Forecast, by Injection (2019-2030)
12.3.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.2. Market Revenue and Forecast, by Injection (2019-2030)
12.4.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.4.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.5.2. Market Revenue and Forecast, by Injection (2019-2030)
12.4.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.6.2. Market Revenue and Forecast, by Injection (2019-2030)
12.4.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.7.2. Market Revenue and Forecast, by Injection (2019-2030)
12.4.7.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product (2019-2030)
12.4.8.2. Market Revenue and Forecast, by Injection (2019-2030)
12.4.8.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.2. Market Revenue and Forecast, by Injection (2019-2030)
12.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.5.2. Market Revenue and Forecast, by Injection (2019-2030)
12.5.5.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product (2019-2030)
12.5.6.2. Market Revenue and Forecast, by Injection (2019-2030)
12.5.6.3. Market Revenue and Forecast, by Joint Type (2019-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Type (2019-2030)
Chapter 13. Company Profiles
13.1. Online Pharmacies
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Bioventus
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Ferring Pharmaceuticals Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Sanofi
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Zimmer Biomet Holdings Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Allergen Plc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pfizer Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Chugai Pharmaceutical Co. Ltd
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. SEIKAGAKU Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Ferring B.V.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1449
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
